Canterbury DHB completes evaluation of Microdacyn

Canterbury DHB completes evaluation of Microdacyn

February 8 2016

Chronic wounds affect thousands of New Zealanders each year. Importantly for our health system Chronic Wounds account for over $250 million of healthcare spend annually. We have to resort to performing over 400 amputation surgeries each year. For the individuals themselves an active chronic wound may reduce quality of life down to just 45% of normal.


Microdacyn Super-oxidised solution is a recently introduced technology for New Zealand. Randomised clinical trials of Microdacyn show a significant reduction in the time to heal of wounds such as chronic ulcers.

For the people of Canterbury Microdacyn is now formally approved for use within the DHB. 

Product_2Te Arai BioFarma are proud to be introducing new technology to improve New Zealanders health outcomes. Microdacyn is now available for use in a number of DHBs, General Practices, podiatry practices and pharmacies.


< Back to News